NZ595737A - Process for the production of safinamide and ralfinamide - Google Patents

Process for the production of safinamide and ralfinamide

Info

Publication number
NZ595737A
NZ595737A NZ595737A NZ59573707A NZ595737A NZ 595737 A NZ595737 A NZ 595737A NZ 595737 A NZ595737 A NZ 595737A NZ 59573707 A NZ59573707 A NZ 59573707A NZ 595737 A NZ595737 A NZ 595737A
Authority
NZ
New Zealand
Prior art keywords
ralfinamide
safinamide
fluorobenzyloxy
propanamide
fluorobenzyl
Prior art date
Application number
NZ595737A
Other languages
English (en)
Inventor
Elena Barbanti
Carla Caccia
Patricia Salvati
Francesco Velardi
Tiziano Ruffilli
Luigi Bogogna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ595737(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NZ595737A publication Critical patent/NZ595737A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595737A 2006-06-19 2007-06-08 Process for the production of safinamide and ralfinamide NZ595737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
NZ572798A NZ572798A (en) 2006-06-19 2007-06-08 Process for the production of safinamide and ralfinamide

Publications (1)

Publication Number Publication Date
NZ595737A true NZ595737A (en) 2013-04-26

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ595737A NZ595737A (en) 2006-06-19 2007-06-08 Process for the production of safinamide and ralfinamide
NZ572798A NZ572798A (en) 2006-06-19 2007-06-08 Process for the production of safinamide and ralfinamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ572798A NZ572798A (en) 2006-06-19 2007-06-08 Process for the production of safinamide and ralfinamide

Country Status (26)

Country Link
US (2) US8076515B2 (enExample)
EP (2) EP2474521B1 (enExample)
JP (2) JP5240476B2 (enExample)
KR (2) KR101410291B1 (enExample)
CN (2) CN103284984B (enExample)
AR (1) AR061510A1 (enExample)
AU (1) AU2007263328C1 (enExample)
BR (1) BRPI0712936B8 (enExample)
CA (1) CA2653012C (enExample)
CY (2) CY1115951T1 (enExample)
DK (2) DK2474521T3 (enExample)
EA (2) EA025326B1 (enExample)
ES (2) ES2602069T3 (enExample)
HR (2) HRP20150136T1 (enExample)
HU (1) HUE030233T2 (enExample)
IL (1) IL195294A (enExample)
LT (1) LT2474521T (enExample)
MX (2) MX2008015704A (enExample)
NO (2) NO342018B1 (enExample)
NZ (2) NZ595737A (enExample)
PL (2) PL2029524T3 (enExample)
PT (2) PT2474521T (enExample)
RS (2) RS55464B1 (enExample)
SI (2) SI2029524T1 (enExample)
TW (2) TWI393700B (enExample)
WO (1) WO2007147491A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413982A (pt) * 2003-08-25 2006-11-07 Newron Pharm Spa derivados de alfa-aminoamida úteis como agentes anti-inflamatórios
JP5240476B2 (ja) * 2006-06-19 2013-07-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
DK2229351T3 (en) 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
SI2563355T1 (sl) * 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
JP2016501212A (ja) 2012-12-03 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ステアロイル−ＣｏＡデサチュラーゼ１（ＳＣＤ１）の阻害剤としての置換イソオキサゾールアミド化合物
WO2014178083A1 (en) 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research An improved synthesis of anti-parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN113072436A (zh) * 2015-07-24 2021-07-06 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es) * 2019-08-06 2024-08-26 Medichem Sa Proceso para preparar safinamida
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
WO2025022300A1 (en) 2023-07-25 2025-01-30 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of safinamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4961001A (en) 2000-03-31 2001-10-15 Cocensys Inc Aminopyridines and their use as anticonvulsants and sodium channel blockers
IL160523A0 (en) * 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
BRPI0413982A (pt) * 2003-08-25 2006-11-07 Newron Pharm Spa derivados de alfa-aminoamida úteis como agentes anti-inflamatórios
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP5240476B2 (ja) * 2006-06-19 2013-07-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
DK2229351T3 (en) * 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
JP5736175B2 (ja) * 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体

Also Published As

Publication number Publication date
MX342698B (es) 2016-10-10
TW200815322A (en) 2008-04-01
NO20171916A1 (no) 2009-01-16
NO20090231L (no) 2009-01-16
NZ572798A (en) 2011-11-25
LT2474521T (lt) 2016-11-25
ES2527437T3 (es) 2015-01-26
US20090156678A1 (en) 2009-06-18
JP5795342B2 (ja) 2015-10-14
EA201101308A1 (ru) 2012-02-28
EA200970028A1 (ru) 2009-06-30
KR20090021392A (ko) 2009-03-03
PT2474521T (pt) 2016-11-10
KR20140027563A (ko) 2014-03-06
EP2029524B1 (en) 2014-11-26
EP2029524A1 (en) 2009-03-04
CN101472880A (zh) 2009-07-01
TWI393700B (zh) 2013-04-21
US8278485B2 (en) 2012-10-02
CY1118113T1 (el) 2017-06-28
TWI412512B (zh) 2013-10-21
HRP20161456T1 (hr) 2016-12-16
AU2007263328A1 (en) 2007-12-27
DK2474521T3 (en) 2016-10-31
KR101410291B1 (ko) 2014-06-20
BRPI0712936B8 (pt) 2021-05-25
SI2474521T1 (sl) 2016-12-30
CN103284984A (zh) 2013-09-11
CA2653012C (en) 2014-08-05
JP2013139446A (ja) 2013-07-18
PL2474521T3 (pl) 2017-01-31
DK2029524T3 (da) 2015-02-23
AR061510A1 (es) 2008-09-03
AU2007263328A2 (en) 2009-02-19
JP5240476B2 (ja) 2013-07-17
NO342018B1 (no) 2018-03-12
HUE030233T2 (en) 2017-04-28
JP2009541232A (ja) 2009-11-26
CN101472880B (zh) 2013-04-24
SI2029524T1 (sl) 2015-03-31
MX2008015704A (es) 2009-01-09
RS55464B1 (sr) 2017-04-28
PT2029524E (pt) 2015-03-09
PL2029524T3 (pl) 2015-04-30
IL195294A (en) 2015-03-31
AU2007263328C1 (en) 2012-09-06
BRPI0712936B1 (pt) 2021-02-23
CA2653012A1 (en) 2007-12-27
EP2474521B1 (en) 2016-08-10
WO2007147491A1 (en) 2007-12-27
CN103284984B (zh) 2016-08-03
IL195294A0 (en) 2009-08-03
ES2602069T3 (es) 2017-02-17
US20120157712A1 (en) 2012-06-21
NO342644B1 (no) 2018-06-25
CY1115951T1 (el) 2017-01-25
US8076515B2 (en) 2011-12-13
AU2007263328B2 (en) 2012-03-22
EA025326B1 (ru) 2016-12-30
HK1130245A1 (en) 2009-12-24
RS53824B1 (sr) 2015-06-30
KR101491541B1 (ko) 2015-02-09
EA017123B1 (ru) 2012-10-30
EP2474521A1 (en) 2012-07-11
HRP20150136T1 (xx) 2015-03-13
TW201313662A (zh) 2013-04-01
BRPI0712936A2 (pt) 2012-12-18

Similar Documents

Publication Publication Date Title
NZ595737A (en) Process for the production of safinamide and ralfinamide
NZ603876A (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
MX2010009561A (es) Compuestos amida, composiciones y usos de los mismos.
MX2012005450A (es) Constructo de vector virico novedoso para sintesis dopa continua optimizada especificamente de neuronas in vivo.
TNSN08417A1 (en) Inhibitors of 11-beta- hydroxysteroid dehydrogenase 1
MX2011008276A (es) Inhibidores de quinasa jun n-terminal.
SI2021337T1 (sl) Inhibitorji beta hidroksisteroidne dehidrogenaze
MY151726A (en) Process for production of prasugrel hydrochloride having high purity
MX2009013742A (es) 2-imidazolinas.
MX337190B (es) Nuevas bencensulfonamidas como bloqueadores del canal de calcio.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2010062927A3 (en) Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
MX2010007392A (es) Antagonistas de trpa1.
TR201901175T4 (tr) Erimiş cüruf kullanarak indirgeyici taşın imal edilmesine yönelik yöntem.
MX2010007391A (es) Antagonistas de trpa1.
MY157116A (en) Novel seh inhibitors and their use
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
MX2015001108A (es) Derivados de triazol carboxamida.
ZA200810031B (en) 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments
IN2012DN03846A (enExample)
NO20091936L (no) 4-imidazoliner som TAAR ligander
IN2012DN01231A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUN 2014 BY HENRY HUGHES

Effective date: 20130913

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUN 2017 BY COMPUTER PACKAGES INC

Effective date: 20140628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2026 BY COMPUTER PACKAGES INC

Effective date: 20250517